ReGen Biologics

Completes $6 mil. private financing, including a $4 mil. preferred equity investment and a $2 mil. line of credit from Sulzer Medica. The funding will be used in part to prepare for the market launch of the firm's flagship collagen-based ReGen meniscus implant in Europe in 2000. The device, intended for regeneration and regrowth of damaged meniscal knee cartilage, is currently in pivotal multi-center trials in the U.S. The privately held, Redwood City, California company also plans to launch the SharpShooter meniscal repair system in the [U.S.] and internationally in the second half of 1999. The disposable SharpShooter device "helps to reduce the time and resources required to repair torn menisci," ReGen claims

More from Archive

More from Medtech Insight